vs
Side-by-side financial comparison of Maison Solutions Inc. (MSS) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Maison Solutions Inc. is the larger business by last-quarter revenue ($27.6M vs $18.6M, roughly 1.5× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -18.0%, a 83.7% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -10.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 42.5%).
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
MSS vs SCYX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $18.6M |
| Net Profit | $-5.0M | $12.3M |
| Gross Margin | 23.4% | — |
| Operating Margin | -4.9% | 56.3% |
| Net Margin | -18.0% | 65.7% |
| Revenue YoY | -10.9% | 1808.5% |
| Net Profit YoY | -1840.5% | 376.5% |
| EPS (diluted) | $-0.23 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.6M | $18.6M | ||
| Q3 25 | $27.2M | $334.0K | ||
| Q2 25 | $34.4M | $1.4M | ||
| Q1 25 | $32.3M | $257.0K | ||
| Q4 24 | $29.4M | $977.0K | ||
| Q3 24 | $28.2M | $660.0K | ||
| Q2 24 | $16.9M | $736.0K | ||
| Q1 24 | $13.6M | $1.4M |
| Q4 25 | $-5.0M | $12.3M | ||
| Q3 25 | $-1.5M | $-8.6M | ||
| Q2 25 | $-287.4K | $-6.9M | ||
| Q1 25 | $1.0M | $-5.4M | ||
| Q4 24 | $-256.0K | — | ||
| Q3 24 | $700.9K | $-2.8M | ||
| Q2 24 | $-2.8M | $-14.5M | ||
| Q1 24 | $-549.0K | $411.0K |
| Q4 25 | 23.4% | — | ||
| Q3 25 | 24.1% | — | ||
| Q2 25 | 9.5% | — | ||
| Q1 25 | 21.8% | — | ||
| Q4 24 | 26.9% | — | ||
| Q3 24 | 28.9% | — | ||
| Q2 24 | 13.0% | — | ||
| Q1 24 | 23.4% | — |
| Q4 25 | -4.9% | 56.3% | ||
| Q3 25 | 0.7% | -2516.5% | ||
| Q2 25 | -15.9% | -701.0% | ||
| Q1 25 | 3.7% | -3350.2% | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 7.3% | -1563.6% | ||
| Q2 24 | -14.4% | -1255.0% | ||
| Q1 24 | -2.3% | -692.5% |
| Q4 25 | -18.0% | 65.7% | ||
| Q3 25 | -5.7% | -2572.2% | ||
| Q2 25 | -0.8% | -504.8% | ||
| Q1 25 | 3.1% | -2097.7% | ||
| Q4 24 | -0.9% | — | ||
| Q3 24 | 2.5% | -425.5% | ||
| Q2 24 | -16.4% | -1964.4% | ||
| Q1 24 | -4.0% | 29.9% |
| Q4 25 | $-0.23 | $0.25 | ||
| Q3 25 | $-0.08 | $-0.17 | ||
| Q2 25 | $-0.02 | $-0.14 | ||
| Q1 25 | $0.06 | $-0.11 | ||
| Q4 24 | $-0.01 | — | ||
| Q3 24 | $0.04 | $-0.06 | ||
| Q2 24 | $-0.16 | $-0.30 | ||
| Q1 24 | $-0.03 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $2.6M | — |
| Stockholders' EquityBook value | $11.6M | $49.4M |
| Total Assets | $75.4M | $59.0M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | $1.1M | $37.9M | ||
| Q2 25 | $775.4K | $44.8M | ||
| Q1 25 | $445.4K | $40.6M | ||
| Q4 24 | $355.7K | $59.3M | ||
| Q3 24 | $588.9K | $68.8M | ||
| Q2 24 | $2.1M | $73.0M | ||
| Q1 24 | $9.4M | $80.2M |
| Q4 25 | $2.6M | — | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | $2.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.5M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | $11.6M | $49.4M | ||
| Q3 25 | $10.1M | $36.4M | ||
| Q2 25 | $11.7M | $44.5M | ||
| Q1 25 | $12.0M | $50.5M | ||
| Q4 24 | $10.9M | $55.1M | ||
| Q3 24 | $11.2M | $58.5M | ||
| Q2 24 | $10.5M | $60.4M | ||
| Q1 24 | $13.3M | $74.1M |
| Q4 25 | $75.4M | $59.0M | ||
| Q3 25 | $73.3M | $51.1M | ||
| Q2 25 | $77.4M | $60.7M | ||
| Q1 25 | $82.7M | $67.9M | ||
| Q4 24 | $82.7M | $90.6M | ||
| Q3 24 | $82.1M | $99.0M | ||
| Q2 24 | $82.4M | $107.8M | ||
| Q1 24 | $44.2M | $118.3M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.26× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $18.4M | ||
| Q3 25 | $1.1M | $-8.7M | ||
| Q2 25 | $-1.6M | $-7.5M | ||
| Q1 25 | $1.7M | $-7.5M | ||
| Q4 24 | $1.1M | $-24.0M | ||
| Q3 24 | $3.6M | $765.0K | ||
| Q2 24 | $-2.6M | $-10.9M | ||
| Q1 24 | $-1.4M | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.66× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.12× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
